Free Trial
→ Trump, Schiff and Dalio all point to the same warning sign (From USA Capital Gold) (Ad)tc pixel
NASDAQ:ANNX

Annexon Q1 2025 Earnings Results & Report

Annexon logo
$4.21 -0.02 (-0.47%)
Closing price 11/10/2026 04:00 PM Eastern
Extended Trading
$4.26 +0.05 (+1.19%)
As of 08:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Annexon missed analyst earnings expectations in its Q1 2025 results, released May 12, 2025. The company reported EPS of -$0.37 versus the -$0.30 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
12:30 PM ET

Annexon EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.30
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Annexon Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Annexon's Q1 2025 Press ReleasePress Release
(8-K)
Annexon's Q1 2025 Quarterly reportQuarterly report
(10-Q)

Annexon Q1 2025 Earnings FAQ

Annexon (NASDAQ:ANNX) reported earnings of -$0.37 per share for Q1 2025, missing the consensus estimate of -$0.30. The report was announced on Monday, May 12, 2025.

Annexon Earnings Headlines

Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
November 9 at 8:31 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/annexon-reports-third-quarter-2026-210100891.html
Annexon (ANNX) Projected to Announce Earnings on Monday
November 8 at 2:26 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31185334
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
November 11 at 1:00 AM  |  Profits Run (Ad)
Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy - Slideshow
November 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4964781-annexon-inc-annx-discusses-vonaprument-phase-iii-archer-ii-trial-in-geographic-atrophy
Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy Transcript
November 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4961867-annexon-inc-annx-discusses-vonaprument-phase-iii-archer-ii-trial-in-geographic-atrophy
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
October 28, 2026  |  marketscreener.comM
See More Annexon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Annexon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annexon and other key companies, straight to your email.

About Annexon

Annexon (NASDAQ:ANNX) is a clinical-stage biopharmaceutical company developing antibody-based therapies for diseases driven by the complement system, a part of the immune system involved in inflammation and tissue damage. The company focuses on the classical complement pathway, which it aims to inhibit selectively.

Its investigational programs are designed for complement-related autoimmune, inflammatory and neurodegenerative conditions. These include treatments being studied for disorders affecting the nervous system and the eye. Annexon’s candidates remain in development and are not approved medicines.

Founded in 2011, Annexon is headquartered in Brisbane, California. The company conducts clinical development and research to advance its antibody therapies.

View Annexon Profile
Earnings Tools